2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer at University of Barcelona, discusses the impact of the recent progress in the second-line treatment setting for hepatocellular carcinoma.
Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the impact of the recent progress in the second-line treatment setting for hepatocellular carcinoma (HCC).
With the FDA approval of regorafenib (Stivarga) for patients with HCC who have progressed on prior sorafenib (Nexavar) treatment, this once dismal disease landscape has been reinvigorated.
These advancements, says Bruix, are extremely beneficial for the patients—but also for physicians and the community, who had felt there was no hope in treatment beyond sorafenib.